Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President, Clinical Development

NEW YORK, May 09, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Stephanie Noviello, MD, MPH has joined the Company as Vice President, Clinical Development.  She will report to David Huang, MD, PhD, Chief Medical Officer.  Dr. Noviello will be a key contributor to the European Marketing Authorisation Application submission for iclaprim.

Dr. Noviello joins Motif Bio from Bristol-Myers Squibb, where she most recently was Clinical Program Lead, Virology.  In this position, she served as clinical lead for the hepatitis B and C and HIV portfolios.  She previously wor…


Leave a Reply

Your email address will not be published.